| 초록 |
Mesenchymal stem cell (MSC) therapy has emerged as a potential treatment for chronic diseases due to its regenerative ability. However, it has significant limitations such as cell’s movement, changing into inappropriate cell types, or growth of tumors. In order to overcome these risks, a revolutionary cell-free therapy was developed to treat the chronic disease, particularly hepatic fibrosis, by using human adipose stem cell-derived exosomes (hADSC-exos). The hADSC-exos were isolated from conditioned media of ADSCs using tangential flow filtration (TFF) method, then were suspended in PBS and stored at -80°C. After intravenous injected into the liver-fibrotic mice, hADSC-exos preferred to maintain inside the livers, especially in damaged liver tissue, notably suppressed fibrogenic markers and finally restored hepatic functions. In conclusion, exosomes derived from hADSC have a dramatic potential to treat chronic hepatic fibrosis. |
